Market closed
Axsome Therapeutics/$AXSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Ticker
$AXSM
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
712
ISIN
US05464T1043
Website
AXSM Metrics
BasicAdvanced
$5.2B
-
-$5.77
0.45
-
Price and volume
Market cap
$5.2B
Beta
0.45
52-week high
$139.13
52-week low
$64.11
Average daily volume
828K
Financial strength
Current ratio
2.028
Quick ratio
1.895
Long term debt to equity
392.749
Total debt to equity
393.602
Interest coverage (TTM)
-22.26%
Management effectiveness
Return on assets (TTM)
-26.18%
Return on equity (TTM)
-282.16%
Valuation
Price to revenue (TTM)
11.806
Price to book
97.75
Price to tangible book (TTM)
-1,250.49
Price to free cash flow (TTM)
-42.937
Growth
Revenue change (TTM)
72.16%
Earnings per share change (TTM)
-9.68%
3-year earnings per share growth (CAGR)
15.75%
What the Analysts think about AXSM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
AXSM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AXSM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AXSM News
AllArticlesVideos
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
GlobeNewsWire·2 days ago
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
Seeking Alpha·1 week ago
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Seeking Alpha·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Axsome Therapeutics stock?
Axsome Therapeutics (AXSM) has a market cap of $5.2B as of May 15, 2025.
What is the P/E ratio for Axsome Therapeutics stock?
The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of May 15, 2025.
Does Axsome Therapeutics stock pay dividends?
No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Axsome Therapeutics dividend payment date?
Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Axsome Therapeutics?
Axsome Therapeutics (AXSM) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.